{"brief_title": "Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients", "brief_summary": "The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.", "condition": "Ocular Hypertension", "intervention_type": "Drug", "intervention_name": "AL-12182 0.03% Ophthalmic Solution", "description": "Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension", "arm_group_label": "AL-12182 0.03%", "criteria": "Inclusion Criteria: - 18 years or older. - Diagnosis of open-angle glaucoma or ocular hypertension. - LogMAR visual acuity not worse than 0.6. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Clinically relevant ophthalmic or systemic conditions. - Other protocol-defined exclusion criteria may apply.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00069706.xml"}